Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Fineline Cube Jan 15, 2026
Company Deals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Fineline Cube Jan 15, 2026
Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Fineline Cube Jan 15, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Deals

Sinopharm and Fresenius Kabi Expand Partnership to Enhance Drug Distribution and Healthcare Services

Fineline Cube Mar 21, 2024

China’s state-owned Sinopharm Group Co., Ltd. (HKG: 1099) has announced a new partnership with Germany’s...

Company Deals

Bayer and Thermo Fisher Partner to Develop Rapid Companion Diagnostics for Precision Oncology

Fineline Cube Mar 21, 2024

Germany’s Bayer (NYSE: BAYE) has entered into a strategic partnership with U.S. life sciences leader...

Company Drug

iRegene’s NouvSight001 Gains Orphan Drug Designation for Retinitis Pigmentosa Treatment

Fineline Cube Mar 21, 2024

Wuhan-based cell therapy innovator iRegene has secured Orphan Drug Designation (ODD) from the U.S. FDA...

Company Drug

BMS Reports Positive Phase III Results for Opdivo and Yervoy in Advanced HCC

Fineline Cube Mar 21, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) announced this week that its Phase III study evaluating...

Company Deals

China Resources Guangdong Pharmaceutical Partners with BD to Enhance Drug and Device Distribution in GBA

Fineline Cube Mar 21, 2024

China Resources Guangdong Pharmaceutical Co., Ltd has entered into a strategic partnership with U.S.-based Becton,...

Digital R&D

CAIR Launches CARES Copilot 1.0: A Revolutionary AI Chatbot for Medical Diagnosis and Treatment

Fineline Cube Mar 21, 2024

The Centre for Artificial Intelligence and Robotics (CAIR), part of the Chinese Academy of Sciences...

Company Deals

VIVA Biotech Secures Licensing Deal with Lonza for Advanced Bispecific Antibody Technology

Fineline Cube Mar 21, 2024

VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a...

Company Drug

Antengene’s ATG-022 Advances to Dose Expansion Phase in Phase II CLINCH Study for Solid Tumors

Fineline Cube Mar 21, 2024

Antengene Corporation Ltd (HKG: 6996), a leading biopharmaceutical company based in China, has announced that...

Company Drug

CSPC Pharmaceutical Secures NMPA Approval for Clinical Study of SYS6023 in Advanced Solid Tumors

Fineline Cube Mar 21, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent China-based biopharmaceutical company, has received approval from...

Company

3SBio Reports 13.8% Revenue Growth in 2023, Driven by Strong Sales of Core Biologics

Fineline Cube Mar 21, 2024

3SBio Inc. (HKG: 1530), a leading China-based biopharmaceutical company, has reported its 2023 financial results,...

Company

Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales

Fineline Cube Mar 21, 2024

Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report,...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Phase Ib/II Study of HRS2398 in Advanced Solid Tumors

Fineline Cube Mar 20, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets

Fineline Cube Mar 20, 2024

Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement...

Company Drug

CSPC Pharmaceutical Gets NMPA Greenlight for SYH2039 Clinical Study in Advanced Malignant Tumors

Fineline Cube Mar 20, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has received...

Company

Novo Nordisk Invests RMB 4 Billion to Expand Sterile Manufacturing in Tianjin

Fineline Cube Mar 20, 2024

Novo Nordisk (NYSE: NVO), a Denmark-based leader in diabetes care, has announced a substantial investment...

Company Deals

Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy

Fineline Cube Mar 20, 2024

Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Policy / Regulatory

China Expands Medical Service Pricing Reform with Three Additional Pilot Provinces

Fineline Cube Mar 20, 2024

The National Healthcare Security Administration (NHSA) has announced an expansion of its medical services pricing...

Company

Swiss Pharma Firm Carbogen Amcis Receives Brazil’s ANVISA GMP Certification for Shanghai Site

Fineline Cube Mar 20, 2024

Carbogen Amcis, a Swiss firm specializing in active pharmaceutical ingredients (APIs) and pharmaceutical process development,...

Company

Everest Medicines Strengthens Leadership with Appointments of Sandra Zeng and Rico Liang

Fineline Cube Mar 20, 2024

Everest Medicines (HKG: 1952), a leading China-based biotechnology company, has announced two significant appointments to...

Company

WuXi XDC Breaks Ground on State-of-the-Art Manufacturing Base in Singapore to Boost ADC Production

Fineline Cube Mar 20, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Posts pagination

1 … 330 331 332 … 609

Recent updates

  • Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
  • Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
  • QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
  • Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific
  • WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Company Digital

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins

Company Deals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.